Galectin-3 as a sex-specific biomarker for cancer and heart failure
Longitudinal PREVEND study shows that increases in galectin-3 predict new-onset cancer and HF in men, but not in women
TribeMD
3 min read
September 25, 2025
Carregando conteúdo…
CardioOncology
Sources
- van den Berg PF, Aboumsallem JP, Screever EM, Shi C, de Wit S, Bracun V, et al. Fibrotic marker galectin-3 identifies males at risk of developing cancer and heart failure. JACC CardioOncol. 2023;5(4):445-53. doi:10.1016/j.jaccao.2023.03.015
Highlights
TribeMD
ASCO GU® 2026
TribeMD
Trastuzumab deruxtecan (T-DXd) Provides Significant Clinical Benefit Over Trastuzumab emtansine (T-DM1), Marking a Potential Shift in the Therapeutic Standard for HER2+ Breast Cancer
TribeMD
SnackableHealth™ | From Intervention to Prevention: How Secondary Prevention Clinics Are Redefining Post-ACS Care
TribeMD
ASCO GU® 2026
TribeMD
Trastuzumab deruxtecan (T-DXd) Provides Significant Clinical Benefit Over Trastuzumab emtansine (T-DM1), Marking a Potential Shift in the Therapeutic Standard for HER2+ Breast Cancer
TribeMD
SnackableHealth™ | From Intervention to Prevention: How Secondary Prevention Clinics Are Redefining Post-ACS Care